NEW YORK (360Dx) –The National Institute of Allergy and Infectious Diseases is sponsoring a clinical study to determine whether low levels of procalcitonin (PCT) can reliably reveal whether a person’s lower respiratory tract infection (LRTI) will improve with antibiotics.
Investigators at the NIAID-supported Antibacterial Resistance Leadership Group are collaborating in the PCT study with researchers and medical experts from BioMérieux, the diagnostics company based in Marcy-l'Étoile, France.